INDEPENDENT STEERING COMMITTEE


The CF RIA program is delighted to welcome an independent Steering Committee of external experts, both clinicians and research scientists in the field of CF to review and assess the submitted applications and award the research grants.

CHAIR

Bonnie Ramsey, MD

Dr Ramsey is the director of the Center for Clinical and Translational Research at Seattle Children’s Research Institute and has led the CF Therapeutics Development Network (TDN) for over 16 years. She is Professor and Vice Chair for research in the Department of Pediatrics and holds the Endowed Chair in Cystic Fibrosis at the University Of Washington School Of Medicine. Dr Ramsey also works as an attending physician at Seattle Children’s Hospital and is Associate director of the CF clinic.

Dr Ramsey is the director of the Center for Clinical and Translational Research at Seattle Children’s Research Institute and has led the CF Therapeutics Development Network (TDN) for over 16 years. She is Professor and Vice Chair for research in the Department of Pediatrics and holds the Endowed Chair in Cystic Fibrosis at the University Of Washington School Of Medicine. Dr Ramsey also works as an attending physician at Seattle Children’s Hospital and is Associate director of the CF clinic.

During her career Dr Ramsey has focused on clinical care and research in the field of CF and is internationally recognized for her work in developing new therapies for patients with CF.  A pioneer in aerosolized antibiotic usage in CF (TOBI), she has been a key investigator in the development of many CF therapies including Pulmozyme, Kalydeco and Orkambi. As co-principal investigator (PI) of the University of Washington Institute for Translational Health Sciences, she has helped set up an extensive clinical research infrastructure at Seattle Children’s Hospital. She is also the PI for a P30 for Cystic Fibrosis Research from the NIDDK.  Her current research interests lie in translational research, especially in the field of cystic fibrosis.

Dr Ramsey is member of the American Pediatric Society and the Association of American Physicians. She is also interested in the ethics of pediatric clinical research and has served on two Institute of Medicine committees focused on this topic. 

READ MORE

STEERING COMMITTEE MEMBER

Michael Knowles, MD

Dr Michael Knowles is a Professor of Pulmonary and Critical Care Medicine at the Marsico Lung Institute and Cystic Fibrosis Research Center at the University of North Carolina (UNC). He is also co-Director of the UNC Adult CF Clinical Center. 

Dr Michael Knowles is a Professor of Pulmonary and Critical Care Medicine at the Marsico Lung Institute and Cystic Fibrosis Research Center at the University of North Carolina (UNC). He is also co-Director of the UNC Adult CF Clinical Center.

He has over 3 decades of clinical research experience that spans across the disciplines of biology, physiology, and design of clinical trials in both the academic and private sectors. His current research interests lie in mucociliary clearance, including primary ciliary dyskinesia; the identification of genes that modulate the severity of the pulmonary phenotype, pseudohypoaldosterism and modifier genes in CF liver disease.

Dr Knowles is currently heading two large multicenter studies: 1) Genetic modifiers ofdDisease phenotype (severity) in CF lung and liver disease, which also includes a recently formed international consortium doing a whole genome scan; and 2) a consortium with 8 sites in North America to study rare genetic disorders of mucociliary clearance.

READ MORE

STEERING COMMITTEE MEMBER

Jeffrey Wine, PhD

Dr Jeffrey Wine is a Benjamin Scott Crocker Professor of Human Biology and the director of the Cystic Fibrosis Research Laboratory at Stanford University in Palo Alto, CA. Dr Wine received his Bachelor’s degree in Psychology from the University of Pittsburgh in 1965 and his Ph.D. in Physiological Psychology from UC Los Angeles in 1971. In 1986 he was named a Professor in the Department of Psychology at Stanford University, a position that he still holds today. Dr Wine also sits on the CF Foundation Research & Research Training Review Panel. 

Dr Jeffrey Wine is a Benjamin Scott Crocker Professor of Human Biology and the director of the Cystic Fibrosis Research Laboratory at Stanford University in Palo Alto, CA. Dr Wine received his Bachelor’s degree in Psychology from the University of Pittsburgh in 1965 and his Ph.D. in Physiological Psychology from UC Los Angeles in 1971. In 1986 he was named a Professor in the Department of Psychology at Stanford University, a position that he still holds today. Dr Wine also sits on the CF Foundation Research & Research Training Review Panel.

As director of the CF Research Laboratory at Stanford University, Dr Wine’s goal is to understand how a defective ion channel leads to CF with an emphasis on ion channels and ion transport involved in gland fluid transport. His laboratory developed the methodology to study individual intact bronchial glands and have now expanded this methodology to the study of sweat glands in vivo in order to track the effects of CFTR-directed therapies.  They were also the first to demonstrate that airway glands, which produce antibiotic-rich mucus that helps protect the airways, display a profound secretory defect in CF patients.

His current research is two-fold: to further understand the role of submucosal glands in protecting the airways from infections; and how the loss of CFTR affects those functions. Also, to develop and refine biomarkers dedicated to increasing the speed with which CFTR-directed therapeutics can reach patients.

READ MORE

STEERING COMMITTEE MEMBER

Patrick Flume, MD

Dr Patrick Flume is currently Professor of Medicine and Pediatrics at the Medical University of South Carolina (MUSC).  He is also the Director of the MUSC CF Center in Charleston, which oversees the largest adult CF program in South Carolina.  The center provides state-of-the-art care to patients and families with CF; serves as primary educator of clinicians and basic scientists in the field of CF; and performs basic and clinical research in the field.  Dr Flume also serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis.  

Dr Patrick Flume is currently Professor of Medicine and Pediatrics at the Medical University of South Carolina (MUSC).  He is also the Director of the MUSC CF Center in Charleston, which oversees the largest adult CF program in South Carolina.  The center provides state-of-the-art care to patients and families with CF; serves as primary educator of clinicians and basic scientists in the field of CF; and performs basic and clinical research in the field.  Dr Flume also serves as the Powers-Huggins Endowed Chair for Cystic Fibrosis.  

Although Dr Flume continues to practice general pulmonary and critical care medicine, his primary interests are in CF, bronchiectasis and non-tuberculous mycobacteria. He has an active clinical research program and chairs the advisory committee for the MUSC General Clinical Research Center.  He is also engaged in the MUSC Clinical and Translation Science Award (CTSA) programme, serving as the Program Director for the Research Center, a member of the Executive Committee for the CTSA, and chair of the Scientific Review Committee. In addition to this, Dr Flume also directs the Cardiopulmonary Exercise Laboratory and the MUSC Pulmonary Rehabilitation Program. 

During the course of his career, Dr Flume has worked on numerous grants and has been an author or peer reviewer for over 100 articles. Recognized by the national and international CF community, he currently serves on the CF Foundation Center Committee, Adult Care Consensus Committee, Advisory Task Force on Adult Issues, and Professional Education Committee.  He also currently co-chairs the Pulmonary Practice Guidelines Committee.

READ MORE

STEERING COMMITTEE MEMBER

Felix Ratjen, MD, FRCP(C)

Dr Felix Ratjen is the Division Chief of Pediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Pediatrics at The University of Toronto, and Senior Scientist at the Research Institute in the Department of Physiology and Experimental Medicine. He holds the Sellers Chair in Cystic Fibrosis from the Sick Kids Foundation. He also co-leads the CF center at Sick Kids and is Medical Director of the Clinical Research Unit.

Dr Felix Ratjen is the Division Chief of Pediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Pediatrics at The University of Toronto, and Senior Scientist at the Research Institute in the Department of Physiology and Experimental Medicine.  He holds the Sellers Chair in Cystic Fibrosis from the Sick Kids Foundation. He also co-leads the CF center at Sick Kids and is Medical Director of the Clinical Research Unit.

Dr Ratjen is currently conducting multiple national and international clinical trials addressing CF lung disease. His research includes investigating new therapeutic strategies to target the underlying defects, treatment of airway infections such as first infection with Pseudomonas aeruginosa, airway inflammation and other important aspects of the disease. In addition, he is involved in developing and validating new outcome measures to quantify important aspects of CF lung disease that can be utilized in clinical trials. Over the recent years Dr Ratjen has developed an interest in other lung disease, specifically in the clinical evaluation of Hereditary Hemorrhagic Telangiectasia (HHT), for which he is leading one of the largest dedicated pediatric clinics.  

A member of several editorial boards including the American Journal of Respiratory and Critical Care Medicine, Thorax, Pediatric Pulmonology and the Journal of Cystic Fibrosis, Dr Ratjen works on multiple grant review panels. He is also a member of the organizing committees of the major respiratory meetings (American Thoracic Society, European Respiratory Society and the North American CF conference).

READ MORE

PrivacyTerms of Use
© 2016 Vertex Pharmaceuticals Incorporated | VXR-HQ-00-00016 | 10/2016
CF RIA program funding is supported by Vertex Pharmaceuticals Incorporated

Vertex and the Vertex triangle logo are trademarks of Vertex Pharmaceuticals Incorporated